Lampalizumab: Difference between revisions
Content deleted Content added
m molar weight unit in g/mol (via AWB script) |
Anypodetos (talk | contribs) Copyedit, clarifications |
||
| Line 17: | Line 17: | ||
| legal_US = |
| legal_US = |
||
| legal_status = Phase 3 |
| legal_status = Phase 3 |
||
| routes_of_administration = Intravitreal |
| routes_of_administration = [[Intravitreal]] |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 34: | Line 34: | ||
}} |
}} |
||
'''Lampalizumab''' ([[International Nonproprietary Name|INN]]) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to [[age-related macular degeneration]]. It binds to [[complement factor D |
'''Lampalizumab''' ([[International Nonproprietary Name|INN]]) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy ([[atrophy]] of the [[retinal pigment epithelium]]) secondary to [[age-related macular degeneration]]. It binds to [[complement factor D]] (CFD).<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref><ref>[http://www.ama-assn.org/resources/doc/usan/lampalizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab], ''[[American Medical Association]]''.</ref> |
||
Enrollment |
Enrollment in Phase 3 [[clinical trials]] was initiated in 2014.<ref>[http://www.pharmatimes.com/Article/14-09-15/Roche_starts_Phase_III_trials_of_eye_drug_lampalizumab.aspx Roche starts Phase III trials of lampalizumab], PharmaTimes</ref> Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.<ref>[http://www.nlm.nih.gov/services/ctphases.html What are clinical trial phases?], NIH - US National Library of Medicine.</ref> |
||
== References == |
== References == |
||
| Line 42: | Line 42: | ||
{{monoclonals for immune system}} |
{{monoclonals for immune system}} |
||
[[Category:Monoclonal antibodies]] |
[[Category:Monoclonal antibodies]] |
||
Revision as of 16:47, 1 December 2016
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | CFD |
| Clinical data | |
| Routes of administration | Intravitreal |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C2068H3214N546O676S13 |
| Molar mass | 46.96 kg/mol g·mol−1 |
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy (atrophy of the retinal pigment epithelium) secondary to age-related macular degeneration. It binds to complement factor D (CFD).[1][2]
Enrollment in Phase 3 clinical trials was initiated in 2014.[3] Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.[4]
References
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
- ^ Roche starts Phase III trials of lampalizumab, PharmaTimes
- ^ What are clinical trial phases?, NIH - US National Library of Medicine.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |